Nemucore Medical Innovations, Inc. Signs Letter of Intent with Xcellerex, Inc.

Nemucore Medical Innovations signs letter of intent with Xcellerex of Marlborough, MA to make use of their innovative modular biomanufacturing equipment.

Worcester, MA (I-Newswire) April 18, 2012 - Nemucore Medical Innovations, Inc. (NMI) of Worcester, MA entered into a letter of intent with Xcellerex, Inc. (Xcellerex) of Marlborough, MA. Xcellerex manufactures the innovative modular platform, designated a FlexFactory®, to be deployed by NMI. Included in this single-use disposable system are controlled environmental modules, XDR bioreactors, and XDM mixing units, which together compose the core of a molecule agnostic manufacturing platform. This platform will be deployed in NMI's 11,000 sqft biomanufacturing space for the production of clinical grade nanomedicine for phase I and II clinical trials.

"The pharmaceutical industry is embracing a fundamental change in the biomanufacturing strategy used for new therapeutic agents," said Christopher McNary, Chief Commercial Officer, of Xcellerex.

"Single-use technologies and flexible manufacturing solutions, such as those pioneered by Xcellerex, are reducing time to clinic and minimizing capital investment and asset utilization risk. We are pleased to support companies such as NMI that are leading the way in developing exciting new biotherapies."

NMI CEO and President, Tim Coleman, said, "Xcellerex's innovative single use equipment will be essential in developing NMI as a national resource for nanomedicine biomanufacturing. Being able to provide access to quality and affordable manufacturing is a big step towards eliminating the present bottlenecks in manufacturing nanomedicines for transition to the clinic."

NMI expects to deploy the FlexFactory® systems in their Worcester facility sometime between the 4th Quarter of 2012 and 1st Quarter of 2013.

About Xcellerex Inc.
Xcellerex is commercializing turnkey biomanufacturing solutions that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. The company's FlexFactory® is a complete modular and portable production train based on single-use technologies, advanced process automation, and compact clean room architecture. FlexFactory allows deployment of GMP manufacturing capacity more rapidly and at greatly reduced costs compared with traditional facilities. Through its BridgeSourcing™ services, Xcellerex manufactures a partner's Biomolecules while the partner prepares for commissioning of its own new FlexFactory. When the partner's facility is ready, Xcellerex deploys its TransPlant™ process to install, validate, and train partner personnel in their own FlexFactory. This parallel-path model both accelerates time to clinical and commercial manufacturing and allows partners to manage the development and market risks associated with adding manufacturing capacity. Xcellerex also leverages its proprietary single-use technologies through the sale of XDR bioreactors, XDM Quad Mixers, and related single-use assemblies. To date, more than 20 therapeutic proteins and vaccines have been manufactured for clinical trials using Xcellerex technology. For more information please visit,

About Nemucore Medical Innovations

Nemucore Medical Innovations, Inc. is dedicated to designing, investigating, developing, and commerc   More..ializing life-saving nanomedicines for the treatment of ovarian cancer. Ultimately, we believe our products will be part of the personalized medicine revolution occurring in cancer therapies. Our unique focus on reducing the complex nature of nanomedicine manufacturing is expected to enhance the speed by which we translate novel therapeutics to the clinic. As a participant in the National Cancer Institute's Centers for Cancer Nanotechnology Excellence, we are building a state of the art biomanufacturing facility as a national resource for nanomedicine and emerging biopharmaceutical community. NMI was founded in 2008 and is based in Worcester and Wellesley, Massachusetts. For more information, please visit

Contact Information

Nemucore Medical Innovations
Susan Keyes
55 Union Street Worcester, MA
Phone : 508-948-0637

Published in:

Science and Research

Published On:

April 18, 2012

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.

Related Releases

LDC Forms Early Drug Discovery Alliance with Daiichi Sankyo
Utilizing shared compound libraries for novel LDC targets.lead discovery center, ldc, daiichi sankyo

Gamry Instruments Launches New Online Shopping Site
Electrochemical Instruments hardware, parts and accessories now available online from Gamry Instruments.

Florida Health Equity Research Institute Established to Identify and Address Health Disparities
Collaboration of Florida's largest universities and health and government organizations serve as the go-to resource for Florida health equity researchers, students, healthcare professionals and the community.

Communication Instead of Collision: Research Project Focuses on the Interaction Between Cyclists and Drivers
As an important contribution to traffic safety, the communication between cyclists and motor vehicle drivers is currently being examined by a scientific project under way in Vienna.

Brill Publishers Selects Scope's ConSCIse Platform for Book Chapter Abstracts
Scope e-Knowledge Center (Scope), a leading provider of knowledge services and a Quatrro Global Services company, has announced that Brill, the international publishing house head-quartered in Leiden, The Netherlands, has selected Scope to support ..